Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Medical Oncology Workload in Europe: One Continent, Several Worlds.

Seruga B, Sullivan R, Fundytus A, Hopman WM, Ocana A, Joffe J, Bodoky G, Le Tourneau C, Vanderpuye V, Lopes G, Hammad N, Sengar M, Brundage MD, Booth CM.

Clin Oncol (R Coll Radiol). 2019 Jul 16. pii: S0936-6555(19)30278-X. doi: 10.1016/j.clon.2019.06.017. [Epub ahead of print]

PMID:
31324474
2.

Cancer care workforce in Africa: perspectives from a global survey.

Vanderpuye V, Hammad N, Martei Y, Hopman WM, Fundytus A, Sullivan R, Seruga B, Lopes G, Sengar M, Brundage MD, Booth CM.

Infect Agent Cancer. 2019 May 21;14:11. doi: 10.1186/s13027-019-0227-8. eCollection 2019.

3.

Medical oncology job satisfaction: Results of a global survey.

Raphael MJ, Fundytus A, Hopman WM, Vanderpuye V, Seruga B, Lopes G, Hammad N, Sengar M, Brundage MD, Sullivan R, Booth CM.

Semin Oncol. 2019 Feb;46(1):73-82. doi: 10.1053/j.seminoncol.2018.12.006. Epub 2019 Jan 2.

PMID:
30685074
4.

A pilot evaluation of the expanded prostate cancer index composite for clinical practice (EPIC-CP) tool in Ontario.

Brundage MD, Barbera L, McCallum F, Howell DM.

Qual Life Res. 2019 Mar;28(3):771-782. doi: 10.1007/s11136-018-2034-x. Epub 2018 Oct 31.

PMID:
30382479
5.

Medical oncology workload in Canada: infrastructure, supports, and delivery of clinical care.

Fundytus A, Hopman WM, Hammad N, Biagi JJ, Sullivan R, Vanderpuye V, Seruga B, Lopes G, Sengar M, Brundage MD, Booth CM.

Curr Oncol. 2018 Jun;25(3):206-212. doi: 10.3747/co.25.3999. Epub 2018 Jun 28.

6.

Evaluation of a widely available patient decision aid for the treatment of prostate cancer.

Feldman-Stewart D, Tong C, Brundage MD.

Patient Educ Couns. 2018 Oct;101(10):1761-1766. doi: 10.1016/j.pec.2018.04.015. Epub 2018 Apr 24.

PMID:
29729858
7.

Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.

Lemieux J, Brundage MD, Parulekar WR, Goss PE, Ingle JN, Pritchard KI, Celano P, Muss H, Gralow J, Strasser-Weippl K, Whelan K, Tu D, Whelan TJ.

J Clin Oncol. 2018 Feb 20;36(6):563-571. doi: 10.1200/JCO.2017.75.7500. Epub 2018 Jan 12. Erratum in: J Clin Oncol. 2018 May 20;36(15):1540.

8.

Delivery of Global Cancer Care: An International Study of Medical Oncology Workload.

Fundytus A, Sullivan R, Vanderpuye V, Seruga B, Lopes G, Hammad N, Sengar M, Hopman WM, Brundage MD, Booth CM.

J Glob Oncol. 2018 Sep;(4):1-11. doi: 10.1200/JGO.17.00126. Epub 2017 Dec 15.

9.

Variation in Radiotherapy Referral and Treatment for High-risk Pathological Features after Radical Prostatectomy: Results from a Population-based Study.

Jin CJ, Hanna TP, Cook EF, Miao Q, Brundage MD.

Clin Oncol (R Coll Radiol). 2018 Jan;30(1):47-56. doi: 10.1016/j.clon.2017.10.009. Epub 2017 Nov 3.

PMID:
29103854
10.

Measuring the Quality of Personal Care in Patients Undergoing Radiotherapy for Prostate Cancer.

Foley KA, Groome PA, Feldman-Stewart D, Brundage MD, Foley JH, McArdle S, Mackillop WJ.

Clin Oncol (R Coll Radiol). 2017 Dec;29(12):827-834. doi: 10.1016/j.clon.2017.09.004. Epub 2017 Oct 9.

PMID:
29032863
11.

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.

Stark DP, Cook A, Brown JM, Brundage MD, Embleton AC, Kaplan RS, Raja FA, Swart AMW, Velikova G, Qian W, Ledermann JA.

Cancer. 2017 Jul 15;123(14):2752-2761. doi: 10.1002/cncr.30657. Epub 2017 Mar 24.

12.

Directly Improving the Quality of Radiation Treatment Through Peer Review: A Cross-sectional Analysis of Cancer Centers Across a Provincial Cancer Program.

Rouette J, Gutierrez E, O'Donnell J, Reddeman L, Hart M, Foxcroft S, Mitera G, Warde P, Brundage MD; Cancer Care Ontario Radiation Oncology Program Leads; Pan-Canadian Peer Review Steering Committee.

Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):521-529. doi: 10.1016/j.ijrobp.2016.10.017. Epub 2016 Oct 20.

PMID:
28258891
13.

What do these scores mean? Presenting patient-reported outcomes data to patients and clinicians to improve interpretability.

Snyder CF, Smith KC, Bantug ET, Tolbert EE, Blackford AL, Brundage MD; PRO Data Presentation Stakeholder Advisory Board.

Cancer. 2017 May 15;123(10):1848-1859. doi: 10.1002/cncr.30530. Epub 2017 Jan 13.

14.

Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.

Vickers MM, Lee C, Tu D, Wheatley-Price P, Parulekar W, Brundage MD, Moore MJ, Au H, O'Callaghan CJ, Jonker DJ, Ringash J, Goldstein D.

Pancreatology. 2016 Nov - Dec;16(6):1106-1112. doi: 10.1016/j.pan.2016.08.013. Epub 2016 Aug 30.

PMID:
27600995
15.

Quality of Radiation Therapy Referral and Utilisation Post-prostatectomy: A Population-based Study of Time Trends.

Jin CJ, Brundage MD, Cook EF, Miao Q, Hanna TP.

Clin Oncol (R Coll Radiol). 2016 Dec;28(12):783-789. doi: 10.1016/j.clon.2016.07.006. Epub 2016 Jul 25.

PMID:
27461732
16.

Engaging stakeholders to improve presentation of patient-reported outcomes data in clinical practice.

Smith KC, Brundage MD, Tolbert E, Little EA, Bantug ET, Snyder CF; PRO Data Presentation Stakeholder Advisory Board.

Support Care Cancer. 2016 Oct;24(10):4149-57. doi: 10.1007/s00520-016-3240-0. Epub 2016 May 10.

PMID:
27165054
17.

A pan-Canadian survey of peer review practices in radiation oncology.

Caissie A, Rouette J, Jugpal P, Davis CA, Hollenhorst H, O'Donnell J, Mitera G, Brundage MD; Pan-Canadian Peer Review Steering Committee.

Pract Radiat Oncol. 2016 Sep-Oct;6(5):342-351. doi: 10.1016/j.prro.2016.01.014. Epub 2016 Feb 4.

PMID:
27025163
18.

What Aspects of Personal Care Are Most Important to Patients Undergoing Radiation Therapy for Prostate Cancer?

Foley KA, Feldman-Stewart D, Groome PA, Brundage MD, McArdle S, Wallace D, Peng Y, Mackillop WJ.

Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):280-8. doi: 10.1016/j.ijrobp.2015.10.023. Epub 2015 Oct 19. Review.

PMID:
26853337
19.

Cancer Care Professionals' Attitudes Toward Systematic Standardized Symptom Assessment and the Edmonton Symptom Assessment System After Large-Scale Population-Based Implementation in Ontario, Canada.

Pereira JL, Chasen MR, Molloy S, Amernic H, Brundage MD, Green E, Kurkjian S, Krzyzanowska MK, Mahase W, Shabestari O, Tabing R, Klinger CA.

J Pain Symptom Manage. 2016 Apr;51(4):662-672.e8. doi: 10.1016/j.jpainsymman.2015.11.023. Epub 2015 Dec 30.

PMID:
26743641
20.

"I sleep better at night:" How peer review of radiation treatment plans indirectly improves quality of care across radiation treatment programs.

Brundage MD, Hart M, O'Donnell J, Reddeman L, Gutierrez E, Foxcroft S, Warde P; Cancer Care Ontario Radiation Oncology Program Leads and the Pan-Canadian Peer Review Steering Committee.

Pract Radiat Oncol. 2017 Jul - Aug;7(4):281-288. doi: 10.1016/j.prro.2016.11.007. Epub 2016 Nov 24.

PMID:
28330746
21.

Graphical displays of patient-reported outcomes (PRO) for use in clinical practice: What makes a pro picture worth a thousand words?

Bantug ET, Coles T, Smith KC, Snyder CF, Rouette J, Brundage MD; PRO Data Presentation Stakeholder Advisory Board.

Patient Educ Couns. 2016 Apr;99(4):483-490. doi: 10.1016/j.pec.2015.10.027. Epub 2015 Nov 2. Review.

PMID:
26603445
22.

Communicating patient-reported outcome scores using graphic formats: results from a mixed-methods evaluation.

Brundage MD, Smith KC, Little EA, Bantug ET, Snyder CF; PRO Data Presentation Stakeholder Advisory Board.

Qual Life Res. 2015 Oct;24(10):2457-72. doi: 10.1007/s11136-015-0974-y. Epub 2015 May 27.

23.

Integrating health-related quality of life findings from randomized clinical trials into practice: an international study of oncologists' perspectives.

Rouette J, Blazeby J, King M, Calvert M, Peng Y, Meyer RM, Ringash J, Walker M, Brundage MD.

Qual Life Res. 2015 Jun;24(6):1317-25. doi: 10.1007/s11136-014-0871-9. Epub 2014 Nov 29.

PMID:
25432885
24.

Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial.

Chow E, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, Brundage MD, Nabid A, Tissing-Tan CJ, Oei B, Babington S, Demas WF, Wilson CF, Meyer RM, Chen BE, Wong RK.

Lancet Oncol. 2014 Feb;15(2):164-71. doi: 10.1016/S1470-2045(13)70556-4. Epub 2013 Dec 23.

PMID:
24369114
25.

Enhancing the role of case-oriented peer review to improve quality and safety in radiation oncology: Executive summary.

Marks LB, Adams RD, Pawlicki T, Blumberg AL, Hoopes D, Brundage MD, Fraass BA.

Pract Radiat Oncol. 2013 Jul - Sep;3(3):149-156. doi: 10.1016/j.prro.2012.11.010. Epub 2013 Mar 16.

26.

Prostate cancer-specific survival differences in patients treated by radical prostatectomy versus curative radiotherapy.

Degroot JM, Brundage MD, Lam M, Rohland SL, Heaton J, Mackillop WJ, Siemens DR, Groome PA.

Can Urol Assoc J. 2013 May-Jun;7(5-6):E299-305. doi: 10.5489/cuaj.11294. Epub 2013 May 13.

27.

Quality of care indicators and their related outcomes: a population-based study in prostate cancer patients treated with radiotherapy.

Webber C, Brundage MD, Siemens DR, Groome PA.

Radiother Oncol. 2013 Jun;107(3):358-65. doi: 10.1016/j.radonc.2013.04.017. Epub 2013 May 27.

PMID:
23722081
28.

Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension.

Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD; CONSORT PRO Group.

JAMA. 2013 Feb 27;309(8):814-22. doi: 10.1001/jama.2013.879.

PMID:
23443445
29.

A 'year in the life' of health services research in oncology.

Brundage MD, Snyder CF, Bass B.

Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):615-22. doi: 10.1586/erp.12.50. Review.

PMID:
23186402
30.

The impact of explicit values clarification exercises in a patient decision aid emerges after the decision is actually made: evidence from a randomized controlled trial.

Feldman-Stewart D, Tong C, Siemens R, Alibhai S, Pickles T, Robinson J, Brundage MD.

Med Decis Making. 2012 Jul-Aug;32(4):616-26. doi: 10.1177/0272989X11434601. Epub 2012 Jan 27.

PMID:
22287534
31.

Information that affects patients' treatment choices for early stage prostate cancer: a review.

Feldman-Stewart D, Brundage MD, Tong C.

Can J Urol. 2011 Dec;18(6):5998-6006. Review.

PMID:
22166326
32.

Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates.

Groome PA, Rohland SL, Siemens DR, Brundage MD, Heaton J, Mackillop WJ.

Cancer. 2011 Sep 1;117(17):3943-52. doi: 10.1002/cncr.25984. Epub 2011 Feb 24.

33.

Can patient-reported outcome measures identify cancer patients' most bothersome issues?

Snyder CF, Blackford AL, Aaronson NK, Detmar SB, Carducci MA, Brundage MD, Wu AW.

J Clin Oncol. 2011 Mar 20;29(9):1216-20. doi: 10.1200/JCO.2010.33.2080. Epub 2011 Feb 22.

PMID:
21343558
34.

How do interventions designed to improve provider-patient communication work? Illustrative applications of a framework for communication.

Brundage MD, Feldman-Stewart D, Tishelman C.

Acta Oncol. 2010;49(2):136-43. doi: 10.3109/02841860903483684. Review.

PMID:
20100151
35.

Is seeing believing?

Brundage MD.

J Clin Oncol. 2010 Feb 10;28(5):711-3. doi: 10.1200/JCO.2009.25.0720. Epub 2010 Jan 11. No abstract available.

PMID:
20065182
36.

Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.

Au HJ, Karapetis CS, O'Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight GJ, Magoski NM, Brundage MD, Jonker DJ.

J Clin Oncol. 2009 Apr 10;27(11):1822-8. doi: 10.1200/JCO.2008.19.6048. Epub 2009 Mar 9.

PMID:
19273701
37.

The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group.

Courneya KS, Booth CM, Gill S, O'Brien P, Vardy J, Friedenreich CM, Au HJ, Brundage MD, Tu D, Dhillon H, Meyer RM.

Curr Oncol. 2008 Dec;15(6):279-85.

38.

A conceptual framework for patient-provider communication: a tool in the PRO research tool box.

Feldman-Stewart D, Brundage MD.

Qual Life Res. 2009 Feb;18(1):109-14. doi: 10.1007/s11136-008-9417-3. Epub 2008 Nov 29.

PMID:
19043804
39.

Managing skeletal related events resulting from bone metastases.

Wilkinson AN, Viola R, Brundage MD.

BMJ. 2008 Nov 3;337:a2041. doi: 10.1136/bmj.a2041. Review. No abstract available.

PMID:
18981017
40.

Overall information needs of early-stage prostate cancer patients over a decade: highly variable and remarkably stable.

Feldman-Stewart D, Brennenstuhl S, Brundage MD, Siemens DR.

Support Care Cancer. 2009 Apr;17(4):429-35. doi: 10.1007/s00520-008-0514-1. Epub 2008 Oct 2.

PMID:
18830718
41.

The information needed by Canadian early-stage prostate cancer patients for decision-making: stable over a decade.

Feldman-Stewart D, Brennenstuhl S, Brundage MD.

Patient Educ Couns. 2008 Dec;73(3):437-42. doi: 10.1016/j.pec.2008.07.008. Epub 2008 Aug 30.

PMID:
18762405
42.

Approach to primary care follow-up of patients with prostate cancer.

Wilkinson AN, Brundage MD, Siemens R.

Can Fam Physician. 2008 Feb;54(2):204-10. Review.

43.

Further insight into the perception of quantitative information: judgments of gist in treatment decisions.

Feldman-Stewart D, Brundage MD, Zotov V.

Med Decis Making. 2007 Jan-Feb;27(1):34-43.

PMID:
17237451
44.

A randomized controlled trial comparing two educational booklets on prostate cancer.

Feldman-Stewart D, Brundage MD, Siemens R, Skarsgard D.

Can J Urol. 2006 Dec;13(6):3321-6.

PMID:
17187695
45.

A purpose-based evaluation of information for patients: an approach to measuring effectiveness.

Feldman-Stewart D, Brennenstuhl S, Brundage MD.

Patient Educ Couns. 2007 Mar;65(3):311-9. Epub 2006 Oct 2.

PMID:
17014979
46.

An explicit values clarification task: development and validation.

Feldman-Stewart D, Brennenstuhl S, Brundage MD, Roques T.

Patient Educ Couns. 2006 Nov;63(3):350-6. Epub 2006 Jul 21.

PMID:
16860521
47.

Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent.

Boulos DL, Groome PA, Brundage MD, Siemens DR, Mackillop WJ, Heaton JP, Schulze KM, Rohland SL.

Cancer. 2006 Apr 15;106(8):1804-14.

48.

Men considering a hypothetical treatment for prostate cancer: a comparison to patients.

Van Manen L, Feldman-Stewart D, Brundage MD.

Patient Educ Couns. 2006 Apr;61(1):33-42. Epub 2005 Oct 27.

PMID:
16257170
49.

A conceptual framework for patient-professional communication: an application to the cancer context.

Feldman-Stewart D, Brundage MD, Tishelman C; SCRN Communication Team.

Psychooncology. 2005 Oct;14(10):801-9; discussion 810-1.

PMID:
16200514
50.

Patient-professional communication research in cancer: an integrative review of research methods in the context of a conceptual framework.

Carlson LE, Feldman-Stewart D, Tishelman C, Brundage MD; SCRN Communication Team.

Psychooncology. 2005 Oct;14(10):812-28; discussion 829-30. Review.

PMID:
16200512

Supplemental Content

Loading ...
Support Center